MERZ-AESTHETICS
1.2.2024 09:01:30 CET | Business Wire | Press release
Merz Aesthetics is presenting at the 2024 International Master Course on Aging Science (IMCAS) World Congress a total of 5 abstracts highlighting the field of regenerative aesthetics and how its product portfolio is contributing. This year’s IMCAS is the 25th edition of the largest scientific aesthetics congress worldwide beginning Thursday, February 1st to Saturday, February 3.
“Merz Aesthetics is looking forward to sharing these new findings, as they provide strong scientific evidence to support the evolving field of regenerative aesthetics,” said Terri Phillips, M.D., Chief Medical Affairs Officer, Merz Aesthetics. “We take pride in the innovation of our product portfolio and how it’s helping to shape the future of the aesthetics industry.”
“Our focus in this year’s Merz Aesthetics sponsored symposium at the IMCAS Congress is the future of regenerative biostimulation with Radiesse”, said Gonzalo Mibelli, President EMEA, Merz Aesthetics. “Together with a panel of renowned industry experts we discuss the topic of skin regeneration, share insights into techniques and personalized treatment approaches aligned with our Merz Aesthetics commitment on scientific exchange and innovation.”
Merz Aesthetics organized a program led by notable medical aesthetic experts, participating in various IMCAS sessions and presenting new data throughout the event.
- Merz Aesthetics sponsored symposium “Mastering regenerative biostimulation” – Dr. Gabriela Casabona, Dr. Tatjana Pavicic, Dr. Jani van Loghem, Dr. Bianca Viscomi, Friday, February 2, 2024, 4:00 p.m. – 6:00 p.m. CEST
- Merz Aesthetics support of IMCAS Cadaver Workshop – Anatomist Dr. Nicholas Moellhoff and Aesthetic Specialist Dr. Jonathan Kadouch, Thursday, February 1, 2024, 2:30 p.m. – 3:30 p.m. CEST
- IMCAS Product Analysis Session “Biostimulators” – Dr. Alec McCarthy, Director Regenerative Aesthetics, Merz Aesthetics, Friday, February 2, 2024, 8:30 a.m. ‒ 10:00 a.m. CEST
- IMCAS Product Analysis Session “Toxins” – PH.D. Andy Curry, associate medical director, Merz Aesthetics, Saturday, February 3, 2024, 8:30 a.m. ‒ 10:00 a.m. CEST
- IMCAS Economic Tribune Roundtable – Bob Rhatigan, CEO Merz Aesthetics, Friday, February 2, 2024, 2:00 p.m. – 3:30 p.m. CEST
Booth Talks
- Treatment Options for Hand Rejuvenation - Dr. Elena Bagnenko, Thursday, February 1, 2024, 1:00p.m. – 1.30 p.m.
- Innovative Technique for Tear Trough Correction - Dr. Yahia Hashish, Thursday, February 1, 2024, 3:30p.m. – 4.00 p.m.
- What are THE Really Important Aspects when using CaHA as a Regenerative Biostimulator? - Dr. Gabriela Casabona, Friday, February 2, 10:00 a.m. – 10.30 a.m.
- Advancing Skin Radiance, Dr. Juan Martín Zárate González, Friday, February 2, 1:00 p.m. – 1.30 p.m.
- Combination of Treatments for Improving Skin Quality - Dr. Ana Diez Gandia, Saturday, February 3, 2024, 10:00 a.m. – 10.30 a.m.
E-Poster Presentations
Virtual posters will be available for viewing on-site throughout the congress and displayed on the virtual e-poster platform with detailed abstracts.
- A review of Radiesse as a regenerative aesthetic treatment. Presenting author: Dr. Shino Bay Aguilera. Co-Authors: Dr. Alec McCarthy, Dr. Saami Khalifian, Dr.Z. Paul Lorenc, Dr. Katherine Goldie, Dr. W. Gregory Chernoff
- The evolving field of regenerative aesthetics. Presenting author: Dr. Katherine Goldie
- Physical properties of diluted Radiesse. Presenting author: Dr. Vasanop Vachiramon. Co-authors: Dr. Chayanee Likitwattananurak, Dr. Nawara Sakpuwadol, Dr. Tanat Yongpisarn
- Attraction of fibroblasts by Micro-Focused Ultrasound (MFU-V). Presenting author: Dr. Kay Marquardt. Co-authors: Dr. F. Wegener, Dr. Nils Warfving, Dr. Christian Hartmann, Dr. Dr. Thomas Hengl
- Retrospective case series following patients treated with a combination of CPM-HA and CaHA fillers. Presenting author: Dr. Bianca Viscomi Co-authors: Dr. Yana Yutskovskaya, Dr. Heidi Waldorf, Dr. Ting Song Lim
About Merz Aesthetics
Merz Aesthetics is a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves — however they define it. Clinically proven, its product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with high standards of safety and efficacy. Being family owned for more than 115 years, Merz Aesthetics is known for building unique connections with customers who feel like family. Merz Aesthetics’ global headquarters is in Raleigh, N.C., USA, with a commercial presence in 90 countries worldwide. It is also a part of Merz Group, which was founded in 1908 and is based in Frankfurt, Germany. Learn more at merzaesthetics.com.
Copyright © 2024 Merz Aesthetics GmbH. All rights reserved. MERZ, MERZ AESTHETICS and the MERZ logo are registered trademarks of Merz Pharma GmbH & Co. KGaA.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240201288217/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Align Partners Issues Public Shareholder Letter and Submits Formal Shareholder Proposals to DB Insurance9.2.2026 15:26:00 CET | Press release
Align Partners underscores DBI’s persistent undervaluation (0.40x Adjusted PBR), despite industry-leading profitability, identifying inefficient capital allocation and governance issues as primary driversAlign Partners outlines measures for capital efficiency and governance normalization; requests a revised “Value-up” plan and a formal response from the Board by March 6, 2026The proposals nominate two Independent Directors via separate election and calls for the reinstatement of the Internal Transaction Committee Align Partners Capital Management Inc. (“Align Partners”), a shareholder of DB Insurance Co., Ltd. (KRX:005830) (“DBI” or the “Company”) holding 1.9%, has issued a public shareholder letter to DBI’s Board of Directors aimed at strengthening capital allocation policy and governance oversight, and submitted formal shareholder proposals for the 2026 Annual General Meeting (“AGM”). Despite DBI’s robust fundamentals—including a 16.1% ROE and a 226% K-ICS ratio—the Company trades at
Promega Unveils Cellular Target Engagement Technology Aimed at Expanding the Druggable Proteome at SLAS 20269.2.2026 13:00:00 CET | Press release
TarSeer™ BRETSA™ Target Engagement System enables studies for difficult proteins early in drug discovery Promega Corporation is launching a new live-cell target engagement platform that could close a long-standing gap between biochemical and cellular assays for understudied or difficult-to-interrogate proteins. The TarSeer™ BRETSA™ Target Engagement System is a novel bioluminescence resonance energy transfer-based shift assay for detecting ligand-protein interactions in intact cells using protein denaturation. It gives drug discovery researchers early, target-specific cellular insights by validating weak or early chemical matter and expanding the targets accessible in live-cell drug discovery workflows. The technology will be debuted at the Society for Laboratory Automation and Screening (SLAS) International Conference and Exhibition in Boston, February 7-11, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260206015371/
Eurofins Viracor BioPharma Expands Bioanalytical Capabilities9.2.2026 13:00:00 CET | Press release
Eurofins Viracor BioPharma Services, a long‑standing and trusted partner for clinical trial testing solutions with deep expertise in specialty biomarkers and molecular assays, announces a significant expansion of its service portfolio with the addition of enhanced bioanalytical testing capabilities. These new services are fully aligned with Good Laboratory Practices (GLP) and Good Clinical Practices (GCP), enabling the company to enhance support of biopharmaceutical development programs with greater scientific breadth throughout the drug development workflow. This strategic advancement follows the successful relocation and integration of Eurofins Pharma Bioanalytics Services from St. Charles, Missouri, into Eurofins Viracor BioPharma’s purpose‑built, eleven‑acre facility in Lenexa, Kansas. The bioanalytical organization brings more than two decades of specialized experience in pharmacokinetics, immunogenicity, and biomarker testing. By combining both laboratories’ strengths, Eurofins V
HKTDC to Host World’s Largest One-Stop Jewellery Marketplace9.2.2026 11:37:00 CET | Press release
New Hard Pure Gold Pavilion showcases breakthrough gold technologies Organised by the Hong Kong Trade Development Council (HKTDC), the world’s largest one‑stop jewellery marketplace will return in early March under its proven “Two Shows, Two Venues” format. The 12th Hong Kong International Diamond, Gem & Pearl Show will take place from 2 to 6 March at AsiaWorld‑Expo, featuring a wide range of jewellery raw materials. Also, the 42nd Hong Kong International Jewellery Show will be held from 4 to 8 March at the Hong Kong Convention and Exhibition Centre, showcasing finished jewellery pieces. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260207153040/en/ Hong Kong International Jewellery Show and Hong Kong International Diamond, Gem & Pearl Show Jenny Koo, Deputy Executive Director of the HKTDC, said: “This year’s twin jewellery shows bring together some 4,000 exhibitors from over 40 countries and regions, with nearly 70% coming
FlexTrade Integrates CME Group’s FX Spot+ and EBS Market Offerings for Enhanced FX Trading9.2.2026 11:30:00 CET | Press release
The initiative will see FlexTrade FX clients seamlessly access CME Group’s primary FX markets within FlexFX. FlexTrade Systems(@FlexTrade), a global leader in multi-asset execution and order management systems, today announced an integration with CME Group’s EBS Market central limit order book (CLOB) and its FX Spot+ platform.The move is designed to diversify and deepen the sources of actionable liquidity available to FlexTrade’s FlexFX users through an integration into CME Group's substantial liquidity pools for spots via FX Spot+. Providing firm, anonymous liquidity and no last-look pricing, EBS Market is a venue for both large market participants in search of FX liquidity in an all-to-all CLOB, and for market-making banks hedging FX risk. FX Spot+ further enhances spot liquidity with Futures liquidity from CME Group. This partnership is integral in helping firms further expand FX liquidity and take advantage of global opportunity. Mutual clients of FlexTrade and CME Group can integr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom